QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
Clinical trial NCT07113964 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07113964
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-08-30
- Primary completion
- 2027-03-30
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.